Sort
51,593 grants matching “hepatitis”
QUANTIFYING THE BALANCE BETWEEN VACCINE-INDUCED T CELL PROTECTION AND PATHOLOGY
$414,950Rustom Noshir Antia · Emory University · R01 · FY2014 · AI
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS
$414,925Brian N Finck · Washington University · R01 · FY2016 · DK
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD
$414,914Michael J. Jurczak · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · DK
The role of the Akt/PKB signaling in insulin action
$414,871Morris J Birnbaum · University Of Pennsylvania · R01 · FY2014 · DK
NOVEL THERAPY FOR DIABETES
$414,843Baylor College Of Medicine · R01 · FY2005 · DK
Glucose Counterregulation in Long Standing Type 1 Diabetes
$414,827Michael R Rickels · University Of Pennsylvania · R01 · FY2011 · DK
The Atp7b-/- mouse model of neurological copper toxicity and Wilson Disease
$414,812Jason L Burkhead · University Of Alaska Anchorage · R21 · FY2022 · NS
Regulation of Hepatic Glucose Fluxes
$414,769Roger Gutierrez-Juarez · Albert Einstein College Of Medicine · R01 · FY2008 · DK
PPiSeq: High-Throughput Protein-Protein Interaction Sequencing
$414,751Gavin J Sherlock · Stanford University · R01 · FY2024 · AI
Novel Nucleic Acid Sensing NLRs and Innate Immunity to Viruses
$414,750Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · U19 · FY2015 · AI
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS
$414,730Brian N Finck · Washington University · R01 · FY2017 · DK
GENE THERAPY FOR DYSLIPIDEMIA AND ATHEROSCLEROSIS
$414,718University Of Pennsylvania · P01 · FY2005 · HL
Functional Dynamics of Cytochrome P4503A4
$414,701William M Atkins · University Of Washington · R01 · FY2021 · GM
3/6 COMpAAAS U01: Intervention Study
$414,681David Fiellin · Yale University · U01 · FY2018 · AA
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction
$414,677Scott M Rawls · Temple Univ Of The Commonwealth · R01 · FY2023 · DA
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction
$414,677Scott M Rawls · Temple Univ Of The Commonwealth · R01 · FY2022 · DA
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction
$414,677Scott M Rawls · Temple Univ Of The Commonwealth · R01 · FY2024 · DA
Expression, Regulation and Function of the SULT1C Carcinogen-Activating Enzymes
$414,674Melissa A Runge-Morris · Wayne State University · R01 · FY2014 · ES
Microbiome as Therapeutic Target in Alcoholic Hepatitis
$414,673Bernd G. Schnabl · University Of California, San Diego · U01 · FY2015 · AA
Microbiome as Therapeutic Target in Alcoholic Hepatitis
$414,673Bernd G. Schnabl · University Of California, San Diego · U01 · FY2014 · AA
Them1-Mediated Metabolic Regulation and Pathogenic Role in NAFLD
$414,644David E Cohen · Weill Medical Coll Of Cornell Univ · R01 · FY2016 · DK
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH
$414,576Barry Coller · Rockefeller University · UL1 · FY2010 · RR
IMMUNE RESPONSES TO AAV IN GENE TRANSFER FOR HEMOPHILIA
$414,561Katherine High · Wistar Institute · P01 · FY2007 · HL
Airway Injury Caused by MAA Adducts
$414,547Todd A Wyatt · University Of Nebraska Medical Center · R01 · FY2010 · AA
Identification and characterization of cellular factors involved in HCV entry
$414,473Charles M. Rice · Rockefeller University · R01 · FY2008 · AI